Ausgabe 3/2023
Inhalt (8 Artikel)
PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials
Chenxi Li, Meiqi Hao, Zige Fang, Jiatong Ding, Sijia Duan, Fengming Yi, Yiping Wei, Wenxiong Zhang
Evaluating the indotecan–neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal Emax regressions
Jan H. Beumer, Benjamin C. Kennard, Julianne L. Holleran, Nancy Moore, Jennifer Zlott, Brian M. Miller, Shivaani Kummar, Alice Chen, James Doroshow, Wansu Park, Jogarao Gobburu, Allison Dunn
Determination of 5-azacitidine in human plasma by LC–MS/MS: application to pharmacokinetics pilot study in MDS/AML patients
Melanie Donnette, Loic Osanno, Madeleine Giocanti, Geoffroy Venton, Laure Farnault, Yael Berda-Haddad, Régis Costello, Solas Caroline, L.’Houcine Ouafik, Joseph Ciccolini, Raphaëlle Fanciullino
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
Georgina Meneses-Lorente, Elena Guerini, Francois Mercier, Neil Parrott, Karey Kowalski, Edna Chow-Maneval, Vincent Buchheit, Guillaume Bergthold, Elizabeth Fox, Alex Phipps, Nassim Djebli
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
Loek A. W. de Jong, Marie Lambert, Nielka P. van Erp, Lukas de Vries, Etienne Chatelut, Petronella B. Ottevanger
Assay performance and stability of uracil and dihydrouracil in clinical practice
Jonathan E. Knikman, Hilde Rosing, Henk-Jan Guchelaar, Annemieke Cats, Jos H. Beijnen
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants
Vassilios Aslanis, Robert J. Slack, Alison C. MacKinnon, Catherine McClinton, Susan Tantawi, Lise Gravelle, Ulf J. Nilsson, Hakon Leffler, Ashley Brooks, Sanjeev K. Khindri, Richard P. Marshall, Anders Pedersen, Hans Schambye, Fredrik Zetterberg
Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies
Danielle Shafer, Amanda B. Kagan, Michelle A. Rudek, Maciej Kmieciak, Mary Beth Tombes, Ellen Shrader, Dipankar Bandyopadhyay, Daniel Hudson, Heidi Sankala, Caryn Weir, Jeffrey E. Lancet, Steven Grant